The safety and efficacy of indobufen or aspirin combined with clopidogrel in patients with acute myocardial infarction after percutaneous coronary intervention

References

• Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, Claeys MJ, Dan G-A, Dweck MR, Galbraith M. et al. 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720–10. doi:10.1093/eurheartj/ehad191.
   PubMed Web of Science ®Google Scholar
• Thakker RA, Salazar L, Jazar DA, Bhakta P, Baker B, Patel C, Elbadawi A, Agarwal M, Albaeni A, Saleh M. et al. Coronary artery disease and aspirin intolerance: background and insights on current management. Cardiol Ther. 2022;11(2):175–83. doi:10.1007/s40119-022-00255-9.
   PubMed Web of Science ®Google Scholar
• Michos ED, Ardehali R, Blumenthal RS, Lange RA, Ardehali H. Aspirin and clopidogrel resistance. Mayo Clin Proc. 2006;81(4):518–26. doi:10.4065/81.4.518.
   PubMed Web of Science ®Google Scholar
• Newby LK, Bhapkar MV, White HD, Moliterno DJ, LaPointe NMA, Kandzari DE, Verheugt FWA, Kramer JM, Armstrong PW, Califf RM. Symphony and 2nd symphony investigators. Aspirin use post-acute coronary syndromes: intolerance, bleeding and discontinuation. J Thromb Thrombolysis. 2003;16(3):119–28. doi:10.1023/B:THRO.0000024050.78728.35.
   PubMed Web of Science ®Google Scholar
• Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of Aspirin: meta-analysis. BMJ. 2000;321(7270):1183–7. doi:10.1136/bmj.321.7270.1183.
   PubMed Web of Science ®Google Scholar
• Yang M, Ye Z, Mei L, Ullah I, Tan C, Wang G, Gu Q, Lu Y, Abdus S, Shi L. et al. Pharmacodynamic effects of indobufen compared with aspirin in patients with coronary atherosclerosis. Eur J Clin Pharmacol. 2021;77(12):1815–23. doi:10.1007/s00228-021-03177-y.
   PubMed Web of Science ®Google Scholar
• Liu J, Sun P, Qi X. Reversible and non-competitive inhibition of cyclooxygenase by indobufen for efficient antiplatelet action and relief of gastrointestinal irritation. Pharmaceutics. 2023;15(8):2135. doi:10.3390/pharmaceutics15082135.
   PubMed Web of Science ®Google Scholar
• Barillà F, Pulcinelli FM, Mangieri E, Torromeo C, Tanzilli G, Dominici T, Pellicano M, Paravati V, Acconcia MC, Gaudio C. Clopidogrel plus Indobufen in acute coronary syndrome patients with hypersensitivity to aspirin undergoing percutaneous coronary intervention. Platelets. 2013;24(3):183–8. doi:10.3109/09537104.2012.686072.
   PubMed Web of Science ®Google Scholar
• Latib A, Ielasi A, Ferri L, Chieffo A, Godino C, Carlino M, Montorfano M, Colombo A. Aspirin intolerance and the need for dual antiplatelet therapy after stent implantation: a proposed alternative regimen. Int J Cardiol. 2013;165(3):444–7. doi:10.1016/j.ijcard.2011.08.080.
   PubMed Web of Science ®Google Scholar
• Wu H, Xu L, Zhao X, Zhang H, Cheng K, Wang X, Chen M, Li G, Huang J, Lan J. et al. Option investigators. Indobufen or aspirin on top of clopidogrel after coronary drug-eluting stent implantation (OPTION): a randomized, open-label, end point-blinded, noninferiority trial. Circulation. 2023;147(3):212–22. doi:10.1161/CIRCULATIONAHA.122.062762.
   PubMed Web of Science ®Google Scholar
• Shi Q-P, Luo X-Y, Zhang B, Wang X-G, Zhao J, Xie Q-F, Liu J-H, Liu Y-K, Jiang J, Zheng B. Effect of indobufen vs. aspirin on platelet accumulation in patients with stable coronary heart disease after percutaneous coronary intervention: an open-label crossover study. Front Pharmacol. 2022;13:950719. doi:10.3389/fphar.2022.950719.
   PubMed Web of Science ®Google Scholar
• Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD, Thygesen K, Alpert JS, Jaffe AS. et al. ESC scientific document group. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2019;40(3):237–69. doi:10.1093/eurheartj/ehy462.
   PubMed Web of Science ®Google Scholar
• Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J. et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention. Circulation. 2019;140(3):240–61. doi:10.1161/CIRCULATIONAHA.119.040167.
   PubMed Web of Science ®Google Scholar
• Review Committee Members E, Bittl JA, Baber U, Bradley SM. Duration of dual antiplatelet therapy: a systematic review for the 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation. 2016;134(10):e156–78. doi:10.1161/CIR.0000000000000405.
   PubMed Web of Science ®Google Scholar
• Patrono C, Baigent C, Hirsh J, Roth G. Antiplatelet drugs: American college of chest physicians evidence-based clinical practice guidelines (8th Edition). Chest. 2008;133(6 Suppl):199S–233S. doi:10.1378/chest.08-0672.
   PubMed Web of Science ®Google Scholar
• Lee J-Y, Sung K-C, Choi H-I. Comparison of aspirin and Indobufen in healthy volunteers. Platelets. 2016;27(2):105–9. doi:10.3109/09537104.2015.1042853.
   PubMed Web of Science ®Google Scholar
• De Caterina R, Giannessi D, Bernini W, Lazzerini G, Lavezzari M, Stragliotto E, Biagi G, Coccheri S. A prostacyclin-sparing effect of Indobufen vs. Aspirin. Thromb Haemost. 1996;75(3):510–4. doi:10.1055/s-0038-1650306.
   PubMed Web of Science ®Google Scholar
• Marzo A, Crestani S, Fumagalli I, Giusti A, Lowenthal DT. Endoscopic evaluation of the effects of Indobufen and aspirin in healthy volunteers. Am J Ther. 2004;11(2):98–102. doi:10.1097/00045391-200403000-00004.
   PubMedGoogle Scholar
• Dai C, Liu M, Yang Z, Li Y, Zhou Y, Lu D, Xia Y, Chen A, Li C, Lu H. et al. Real-world performance of indobufen versus aspirin after percutaneous coronary intervention: insights from the aspiration registry. BMC Med. 2024;22(1):148. doi:10.1186/s12916-024-03374-3.
   PubMed Web of Science ®Google Scholar
• Pan Y, Meng X, Yuan B, Johnston SC, Li H, Bath PM, Dong Q, Xu A, Jing J, Lin J. et al. INSURE investigators. Indobufen versus aspirin in patients with acute ischaemic stroke in China (INSURE): a randomised, double-blind, double-dummy, active control, non-inferiority trial. Lancet Neurol. 2023;22(6):485–93. doi:10.1016/S1474-4422(23)00113-8.
   PubMed Web of Science ®Google Scholar
• Baaten CCFMJ, Schröer JR, Floege J, Marx N, Jankowski J, Berger M, Noels H. Platelet abnormalities in CKD and their implications for antiplatelet therapy. Clin J Am Soc Nephrol CJASN. 2022;17(1):155–70. doi:10.2215/CJN.04100321.
   PubMed Web of Science ®Google Scholar
• Melloni C, Cornel JH, Hafley G, Neely ML, Clemmensen P, Zamoryakhin D, Prabhakaran D, White HD, Fox KA, Ohman EM. et al. Impact of chronic kidney disease on long-term ischemic and bleeding outcomes in medically managed patients with acute coronary syndromes: insights from the trilogy ACS trial. Eur Heart J Acute Cardiovasc Care. 2016;5(6):443–54. doi:10.1177/2048872615598631.
   PubMed Web of Science ®Google Scholar
• Gallagher H, Dumbleton J, Maishman T, Whitehead A, Moore MV, Fuat A, Fitzmaurice D, Henderson RA, Lord J, Griffith KE. et al. Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiovascular disease in people with chronic kidney disease. Trials. 2022;23(1):331. doi:10.1186/s13063-022-06132-z.
   PubMed Web of Science ®Google Scholar
• Liu J, Xu D, Xia N, Hou K, Chen S, Wang Y, Li Y. Anticoagulant activities of Indobufen, an antiplatelet drug. Mol Basel Switz. 2018;23(6):1452. doi:10.3390/molecules23061452.
   Google Scholar